For the purpose of issuing and allocating 4 equity shares of Piramal Pharma (PPL) worth Rs10 each for every equity share worth Rs2 granted to PEL shareholders, the record date is set as September 1, 2022.
Piramal’s financial business contributed about 52 per cent of revenue of the company in the financial year 2021-22, whereas the remaining 48 per cent of revenue came from the pharmaceutical business.
In July this year, PEL said it had also received RBI approval for the NBFC licence. Subsequent to the demerger, PEL said as an NBFC it will have a loan book of $9 billion, while the pharma firm will be a significant player with revenues of $1 billion.
Haven’t studied Dhampur bio org. In depth but one thing interesting is although shares split was 1:1 for dhampur bio & mills, & the demerger is done primarily for succession planning & family partition, dhampur sugar mills have more assets although not by a major extent( capacity wise i am yet to study the quality of those) Vs dhampur bio & if the quality of both the brothers as capital allocators is similar ( again a major assumption since yet to study in depth) then there might be some scope for price expansion in dhampur bio as market cap of bio is Rs1000-1100 cr vs 1500 cr of dhampur mills
Add-shop-retail issue :- The co. gave rights in 1:1 ratio for Rs. 54 whn mkt share price was 90. Now, the interesting part here is that promoters mentioned not to participate unless there’s undersubscripn. I applied and got extra shares in ratio of almost 1:10. Sold off arnd Rs. 71. So theoretically almost 170-20 = 50 rs. profit per lot.
This is zerodha’s official spreadsheet of Corporate actions.
It will sync automatically.
It is useful to track the record date of mergers, rights issues, and ipos
The shares are already credited in demat ac they will most probably list in this quarter(December) according to the concall after all necessary approvals.
